Assessment of the safety and hepatic lipid-lowering effects of Lactobacillus delbrueckii subsp. lactis CKDB001

IF 2.3 3区农林科学 Q3 FOOD SCIENCE & TECHNOLOGY

Applied Biological Chemistry Pub Date : 2024-11-22 DOI:10.1186/s13765-024-00949-9

Hyunchae Joung, Jaeryang Chu, Yoo Jin Kwon, Kyung Hwan Kim, Chang Hun Shin, Jung-Heun Ha

{"title":"Assessment of the safety and hepatic lipid-lowering effects of Lactobacillus delbrueckii subsp. lactis CKDB001","authors":"Hyunchae Joung, Jaeryang Chu, Yoo Jin Kwon, Kyung Hwan Kim, Chang Hun Shin, Jung-Heun Ha","doi":"10.1186/s13765-024-00949-9","DOIUrl":null,"url":null,"abstract":"<div>Probiotics have been shown to provide health benefits for several metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD), by modulating the gut microbiota. In this study, we evaluated the safety and efficacy of Lactobacillus delbrueckii subsp. lactis CKDB001 as a potential therapeutic candidate for the treatment of MASLD. We evaluated antibiotic resistance, hemolytic, gelatinase, and bile salt hydrolase activities, and the production of biogenic amines and D-lactate using in vitro analyses. We found that L. lactis CKDB001 treatment resulted in significant anti-adipogenic properties in the HepG2 cell line, reducing lipid accumulation and improving lipid profiles through mechanisms involving the upregulation of SIRT1 and PPARα, and downregulation of CD36 and ELOVL6. These results suggest that L. lactis CKDB001 is a safe and effective probiotic for managing MASLD. Further in vivo studies and clinical trials are required to validate these effects and fully elucidate their therapeutic potential and safety profiles.</div>","PeriodicalId":467,"journal":{"name":"Applied Biological Chemistry","volume":"67 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://applbiolchem.springeropen.com/counter/pdf/10.1186/s13765-024-00949-9","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Biological Chemistry","FirstCategoryId":"97","ListUrlMain":"https://link.springer.com/article/10.1186/s13765-024-00949-9","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"FOOD SCIENCE & TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Probiotics have been shown to provide health benefits for several metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD), by modulating the gut microbiota. In this study, we evaluated the safety and efficacy of Lactobacillus delbrueckii subsp. lactis CKDB001 as a potential therapeutic candidate for the treatment of MASLD. We evaluated antibiotic resistance, hemolytic, gelatinase, and bile salt hydrolase activities, and the production of biogenic amines and D-lactate using in vitro analyses. We found that L. lactis CKDB001 treatment resulted in significant anti-adipogenic properties in the HepG2 cell line, reducing lipid accumulation and improving lipid profiles through mechanisms involving the upregulation of SIRT1 and PPARα, and downregulation of CD36 and ELOVL6. These results suggest that L. lactis CKDB001 is a safe and effective probiotic for managing MASLD. Further in vivo studies and clinical trials are required to validate these effects and fully elucidate their therapeutic potential and safety profiles.

查看原文本刊更多论文

评估德尔布鲁贝克乳杆菌亚种 CKDB001 的安全性和肝脏降脂作用

事实证明，益生菌可通过调节肠道微生物群来治疗多种代谢性疾病，包括肥胖、2 型糖尿病和代谢功能障碍相关性脂肪肝（MASLD）。在本研究中，我们评估了作为治疗 MASLD 潜在候选疗法的德尔布鲁贝克乳杆菌亚种 CKDB001 的安全性和有效性。我们通过体外分析评估了抗生素耐药性、溶血、明胶酶和胆盐水解酶活性以及生物胺和D-乳酸盐的产生。我们发现，L. lactis CKDB001 通过上调 SIRT1 和 PPARα、下调 CD36 和 ELOVL6 的机制，在 HepG2 细胞系中产生了显著的抗脂肪生成特性，减少了脂质积累并改善了脂质特征。这些结果表明，L. lactis CKDB001 是一种安全有效的益生菌，可用于控制 MASLD。要验证这些效果并充分阐明其治疗潜力和安全性，还需要进一步的体内研究和临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Applied Biological Chemistry Chemistry-Organic Chemistry

CiteScore

5.40

自引率

6.20%

发文量

审稿时长

20 weeks

期刊介绍： Applied Biological Chemistry aims to promote the interchange and dissemination of scientific data among researchers in the field of agricultural and biological chemistry. The journal covers biochemistry and molecular biology, medical and biomaterial science, food science, and environmental science as applied to multidisciplinary agriculture.